Abstract
Figure S1. AAV-CRISPRa-APCM approach as a cancer immunotherapy. Figure S2. Dual-AAV-CRISPRa-APCM approach as a cancer immunotherapy. Figure S3. Quality control of the APCM CRISPR activation screen in the E0771 lung metastasis model. Figure S4. AAV-mediated ORF delivery of immunostimulatory factors elicited antitumor responses. Figure S5. Validation of the six-gene combination CLCG4I in the E0771 metastatic tumor model. Figure S6. Evaluation of IL-12 and IL-23 formation in vitro and in vivo following AAVIL12B treatment. Figure S7. Safety evaluation of AAV-4II treatment. Figure S8. AAV-mediated ORF delivery of immunostimulatory molecules promotes immune cell infiltration into the TME. Figure S9. Gating strategy for analyzing tumor-infiltrating immune cell populations. Figure S10. Comparison of pathway enrichment for the bulk RNA-seq data for tumor cells. Figure S11. Comparison of pathway enrichment in tumor cells between AAV-4II and IFNG from the bulk RNA-seq dataset. Figure S12. Comparative transcriptomic analysis of tumor-infiltrating OT-I T cells across AAV treatment groups. Figure S13. Single-cell transcriptomic profiling reveals 4II-induced transcriptional reprogramming of lung-infiltrating T cells. Figure S14. Cell-cell communication and ligand-receptor interaction analysis in AAV-4II treated tumors. Figure S15. CCL and CXCL signaling pathway network following AAV-4II treatment. Figure S16. Ectopic expression of immunostimulatory factors synergizes with human CART cells. Figure S17. Combining AAV-4II with CAR-T cell enhances anti-tumor activity in human tumor models. Figure S18. Signature gene expression in CD8+ CAR-T cells, comparing 4II vs control groups. Figure S19. Differential pathways in CD8+ CAR-T cells, comparing 4II vs control groups. Figure S20. Elevated 4II signature expression is associated with immunotherapy response. Figure S21. Impact of 4II gene signatures on human patient survival in cancer immunotherapy treatment settings.